Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in the United States

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 801-806

  Sun, Peter ^a   Tunceli, Kaan ^b   Zhang, Qiaoyi ^b   Seck, Thomas ^b   Iglay, Kristy ^b   Davies, Michael J ^b   Ambegaonkar, Baishali ^b   Radican, Larry ^b  

^a Kailo Research Group   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Oral antihyperglycemic agents; Statins; Type 2 diabetes; Undertreatment

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; SMOKING; TIME TO TREATMENT; UNITED STATES;

CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84880306858     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.800473     Document Type: Article

References (32)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40
2. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49:S12-154
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
4. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
5. Standards of medical care in diabetes, 2012. Diabetes Care 2012; 35(Suppl 1):S11-63
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
7. Andrews RC, Cooper AR, Montgomery AA, et al. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. Lancet 2011;378:129-39
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
10. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72
11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
12. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
13. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
14. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
15. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
16. Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007;77:126-33
17. Fu AZ, Zhang Q, Davies MJ, et al. Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study. Curr Med Res Opin 2011;27:1035-40
18. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-53
19. Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med 2009;169:1718-20
20. Zhang Q, Rajagopalan S, Marrett E, et al. Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes. Diabetes Obes Metab 2012;14:149-54
21. Sinclair AJ, Alexander CM, Davies MJ, et al. Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes. BMC Endocr Disord 2012;12:1
22. Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007;23:3017-23
23. Crawford AG, Cote C, Couto J, et al. Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States. Popul Health Manag 2010;13:139-50
24. Crawford AG, Cote C, Couto J, et al. Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database. Popul Health Manag 2010;13:151-61
25. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12-54
26. Zhang Q, Zhao C, Davies MJ, et al. Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. Am J Manag Care 2011;17:746-52
27. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report). National Institutes of Health: National Heart, Blood, and Lung Institute, 2001. Available at: http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3full.pdf. Accessed 22 September 2012
28. Parchman ML, Romero RL, Pugh JA. Encounters by patients with type 2 diabetes, complex and demanding: an observational study. Ann Fam Med 2006;4:40-5
29. Merz CN, Buse JB, Tuncer D, et al. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 2002;40:1877-81
30. AB E, Denig P, van Vliet T, et al. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract 2009;10:24
31. Tsang JL, Mendelsohn A, Tan MK, et al. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy. Am J Cardiol 2008;102:1142-5
32. Brouwer ES, West SL, Kluckman M, et al. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. Pharmacoepidemiol Drug Saf 2012;21:920-8